Jiani Wang
Chinese Academy Of Medical Sciences And Peking Union Medical College
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis.
Journal: Thoracic cancer
Published: April 12, 2026
Sleep Disturbance, Treatment-Related Adverse Events, and Psychological Distress in Breast Cancer Patients: A Prospective Cohort Study.
Journal: Patient preference and adherence
Published: March 11, 2026
Spatial transcriptome revealed associated biomarkers for endocrine therapy response in HR-positive/HER2-negative early breast cancer.
Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: December 10, 2025
Dual-Pronged Lipid Nanocarriers Promote Immunotherapy for TNBC by Inducing Immunogenic Cell Death and Activating Lymphoid Immune Cells.
Journal: Research (Washington, D.C.)
Published: December 04, 2025
Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer.
Journal: Breast cancer (Dove Medical Press)
Published: October 23, 2025
Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer.
Journal: Cancer innovation
Published: September 15, 2025
Associations between dynamic hematological indicators and outcomes in HR-positive, HER2-negative metastatic breast cancer treated with bireociclib or placebo plus fulvestrant: Findings from the BRIGHT-2 trial.
Journal: Breast (Edinburgh, Scotland)
Published: June 27, 2025
The Burden of Breast Cancer and its Attributable Risk Factors in 204 Countries and Territories, 1990-2021: Results From the Global Burden of Disease Study 2021.
Journal: Cancer innovation
Published: June 07, 2025
Expert Consensus on Tiered Diagnosis and Treatment of Breast Cancer as a Single-Disease Management Model in China (2025 Edition).
Journal: Cancer innovation
Published: May 16, 2025
Novel Causal Evidence for the Role of Circulating Lipid Metabolites in Breast Cancer Risk: A Bidirectional Mendelian Randomization Analysis.
Journal: Journal of nutrition and metabolism
Published: March 08, 2025
Case Report: Hepatic sarcoidosis-like reaction from neoadjuvant pembrolizumab in early-stage triple-negative breast cancer.
Journal: Frontiers in immunology
Published: March 07, 2025
Last Updated: 09/26/2026